

MB ratified the following decisions from Subcommittees:

Frimley ICB Medicines Optimisation Group (MOG):

- Updates to inhaler choices on formulary – paediatrics: inhaler choices were reviewed based upon efficacy, safety, licensing, carbon footprint and cost. Changes to the formulary to optimise these factors were recommended. MOG recommended that these changes be approved.
- Duloxetine classification: Currently the formulary states that duloxetine use is restricted to diabetic neuropathy. However, NICE recommends use for all neuropathic pain and this is current practice. MOG recommended that this restriction be removed.
- Medicines Optimisation Care Homes Team PRN Protocol: The Medicines Optimisation in Care Homes team have updated the Frimley good practice guidance for PRN Protocols. MOG recommended that this updated guidance be approved.
- Activa Hosiery formulary application to align north and south formularies: Application considered for alignment of formulary across Frimley as regards Activa Hosiery at no additional cost. MOG recommended that this updated guidance be approved.
- PETRUSHKA trial: This National Institute for Health and Care Research (NIHR) approved trial is to be undertaken in two practices in Frimley ICS. Excess treatment costs are provided and the antidepressants used will align with our formulary. MOG recommended that this trial could be approved.
- Use of salbutamol inhalers in schools: This policy statement has been updated to allow greater flexibility for children in primary schools but keeping clarity that inhalers should not be prescribed to be stored at multiple locations. MOG recommended that this policy be approved.
- Asthma posters: Posters showing the Frimley Formulary inhaler choices for children and young people have been produced. MOG recommended that these be approved.
- Medicines Optimisation Care Home (MOCH) Thickeners Charts: The MOCH team have produced administration charts for thickeners, to support safe use. MOG recommended that these be approved.
- Terms of reference update: The ToR have been updated with new job titles for our Medicines Optimisation Transformation Leads. MOG recommended that these be approved.
- Wegovy (semaglutide) pathway: A pathway setting out the place in therapy and referral route for semaglutide for weight loss has been developed. MOG recommended that it be approved.
- Wound care formulary addition – Avelle: A request to change the PICO system to Avelle. This would bring a safety improvement as well as cost reduction. MOG recommended that this change be approved.
- Out of stock guidance for primary care: This guidance supports primary care with what actions to take if a medication is out of stock. MOG recommended that this change be approved.
- SGLT2 adverse drug reactions patient information leaflet – A patient information leaflet has been developed at the request of local PCNs to support patients in being aware of potential ADRs. MOG recommended that this be approved.
- Recent NICE TAs affecting primary care – MOG recommended that Rimegepant for treatment of migraine be “Green” on the Frimley Formulary and that for prophylaxis of migraine it be “Amber no Shared Care”. It was also recommended that Tirzepatide for type 2 diabetes management be “Green”. A decision was not reached on Daridorexant, further discussion of available non-pharmacological alternatives is required.
- Phenobarbital oral solution: There is currently not a low alcohol formulation of phenobarbital solution listed on the formulary. In practice, low alcohol formulations are already prescribed for children. MOG recommended that this be added to the formulary.

Frimley Health Foundation Trust (FHFT) Drugs and Therapeutic Committee (DTC)

- Drugs added to formulary:
 - Acaroid for the treatment of house dust mite allergy, as a Hospital-only (RED) prescribable medication.
 - Nebulised Iloprost for the treatment of Pulmonary Hypertension on ICU
 - Methacholine- for use as a provocation test for Respiratory Challenge
 - Allergovit- agreed as a short-term formulary option due to shortage of Pollinex
- NICE TA approvals. A larger list than usual due to cancellation of October's meeting. All are Hospital-only (RED) medication unless otherwise stated.
 - Birch Bark (HST 28)
 - Pembrolizumab (TA914)
 - Pegunigalsidase alfa (TA915)
 - Bimekizumab (TA916 & 918)
 - Ranibizumab (update to TA 274)
 - Rimegepant (TA919- MB later confirmed **Green** for and or **Amber no shared care** for prophylaxis)
 - Tofacitinib (TA920)
 - Ruxolitinib (TA921)
 - Daridorexant (TA922- MB confirmed **Green** status – additional supporting material to be drafted)
 - Tirzepatide (TA924) - MB confirmed **Green** status for type 2 diabetes
 - Mirikizumab (TA925)
 - Glofitamab (TA927)
 - Daratumab with Lenalidomide (TA917)
- Formulary Status changes
 - Ferracru- change of status from **Red** to **Amber**- pending confirmation of failure rate & costings
- Guidelines discussed:
Wegovy (semaglutide) for weight loss- **Approved**

Frimley Health and Care ICS Antimicrobial Stewardship Group Update

- Frimley Health and Care ICS Antimicrobial Stewardship Group terms of reference approved.
- Collaborative Working Project between Pfizer Limited and Frimley ICS: Integrated Anti-Microbial Stewardship, co-development of on-line AMS education for social care staff, agreed - no objections to the project going ahead.

Frimley ICS Pharmacy Workforce Group Update

- 10 applications for pre-registration pharmacy technicians (PTPT) supported by Frimley ICS (Training Hub, Primary Care School and MOT joint working).
- Previously zero applications made.
- Successful with 4 PTPT placements (2 single sector and 2 multi sector).
- Careers group and volunteers list established.
- Multi-professional Education and Training Investment Plan (METIP) workforce planning tool to forecast shortfalls in supply vs demand reviewed.
- Joint Designated Prescribing Practitioners (DPP) project with Surrey Heartlands ICB; DPP project manager: currently in recruitment process & DPP mentors: job description being finalised.
- Peer group created for foundation trainees within PCNs at Frimley

Other decisions:

Risk Register

MB was made aware of revisions to 4-risk structure as part of new ICB Operating model. Existing risks being migrated over to new structure. Head of Governance to be invited to future meeting to help members identify risk, escalate and align.

NHSE Specialised Commissioning

The following 3 drugs included on formulary and accessible via specialist centres

- Mavacamten (TA 913) – accessed by specialist cardiology centre.
- Birch bark extract for treating epidermolysis bullosa accessed via specialised bullosa services.
- Pegunigalsidase alfa (TA915) for treating Fabry disease accessed by specialist lysosomal storage disorder services.

Terms of Reference

New format for use for Terms of Reference has been agreed ICB-wide. Medicine Boards existing Terms of Reference were adapted into new template and agreed.

Riluzole for motor neurone disease (MND) – shortage

Agreement to switch to prescribing of Rilutek® brand in short term to manage supply constraints